{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05980806",
            "orgStudyIdInfo": {
                "id": "XPORT-MF-044"
            },
            "organization": {
                "fullName": "Karyopharm Therapeutics Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia",
            "officialTitle": "A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia",
            "acronym": "SENTRY-2",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-selinexor-monotherapy-in-subjects-with-jak-inhibitor-myelofibrosis-and-moderate-thrombocytopenia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-24",
            "studyFirstSubmitQcDate": "2023-07-31",
            "studyFirstPostDateStruct": {
                "date": "2023-08-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Karyopharm Therapeutics Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-na\u00efve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study."
        },
        "conditionsModule": {
            "conditions": [
                "Myelofibrosis",
                "Moderate Thrombocytopenia"
            ],
            "keywords": [
                "Myelofibrosis",
                "Selinexor",
                "Total Symptom Score",
                "Myelofibrosis Symptom Assessment Form",
                "Spleen Volume Reduction",
                "TSS50",
                "SVR35",
                "JAK2",
                "KPT-330",
                "Pacritinib",
                "Ruxolitinib",
                "Momelotinib",
                "Thrombocytopenia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 118,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Selinexor 60 mg (Arm 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.",
                    "interventionNames": [
                        "Drug: Selinexor 60 mg",
                        "Drug: Ruxolitinib",
                        "Drug: Pacritinib",
                        "Drug: Momelotinib"
                    ]
                },
                {
                    "label": "Selinexor 40 mg (Arm 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.",
                    "interventionNames": [
                        "Drug: Selinexor 40 mg",
                        "Drug: Ruxolitinib",
                        "Drug: Pacritinib",
                        "Drug: Momelotinib"
                    ]
                },
                {
                    "label": "Selinexor 60 mg (Optional Expansion Arm)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \\[5 mg or 10 mg twice daily\\], pacritinib \\[200 mg twice daily\\], or momelotinib \\[200 mg once daily\\]) may be initiated for participants whose SVR is less than (\\<) 10% at Week 12 or \\<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to \\[\\>=\\] 50 x 10\\^9/L, pacritinib if platelets \\<50 x 10\\^9/L, momelotinib if platelets is \\>=50 x 10\\^9/L and hemoglobin level is \\< 10 gram per deciliter \\[g/dL\\]).",
                    "interventionNames": [
                        "Drug: Selinexor 60 mg",
                        "Drug: Ruxolitinib",
                        "Drug: Pacritinib",
                        "Drug: Momelotinib"
                    ]
                },
                {
                    "label": "Selinexor 40 mg (Optional Expansion Arm)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \\[5 mg or 10 mg twice daily\\], pacritinib \\[200 mg twice daily\\], or momelotinib \\[200 mg once daily\\]) may be initiated for participants whose SVR is \\<10% at Week 12 or \\<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets \\>= 50 x 10\\^9/L, pacritinib if platelets \\<50 x 10\\^9/L, momelotinib if platelets is \\>=50 x 10\\^9/L and hemoglobin level is \\< 10 g/dL).",
                    "interventionNames": [
                        "Drug: Selinexor 40 mg",
                        "Drug: Ruxolitinib",
                        "Drug: Pacritinib",
                        "Drug: Momelotinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Selinexor 60 mg",
                    "description": "Participants will receive selinexor 60 mg oral tablets QW.",
                    "armGroupLabels": [
                        "Selinexor 60 mg (Arm 1)",
                        "Selinexor 60 mg (Optional Expansion Arm)"
                    ],
                    "otherNames": [
                        "KPT-330"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Selinexor 40 mg",
                    "description": "Participants will receive selinexor 40 mg oral tablets QW.",
                    "armGroupLabels": [
                        "Selinexor 40 mg (Arm 2)",
                        "Selinexor 40 mg (Optional Expansion Arm)"
                    ],
                    "otherNames": [
                        "KPT-330"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "description": "Participants will receive ruxolitinib 5 mg or 10 mg twice daily.",
                    "armGroupLabels": [
                        "Selinexor 40 mg (Arm 2)",
                        "Selinexor 40 mg (Optional Expansion Arm)",
                        "Selinexor 60 mg (Arm 1)",
                        "Selinexor 60 mg (Optional Expansion Arm)"
                    ],
                    "otherNames": [
                        "JAKAFI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pacritinib",
                    "description": "Participants will receive pacritinib 200 mg twice daily.",
                    "armGroupLabels": [
                        "Selinexor 40 mg (Arm 2)",
                        "Selinexor 40 mg (Optional Expansion Arm)",
                        "Selinexor 60 mg (Arm 1)",
                        "Selinexor 60 mg (Optional Expansion Arm)"
                    ],
                    "otherNames": [
                        "VONJO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Momelotinib",
                    "description": "Participants will receive momelotinib 200 mg once daily.",
                    "armGroupLabels": [
                        "Selinexor 40 mg (Arm 2)",
                        "Selinexor 40 mg (Optional Expansion Arm)",
                        "Selinexor 60 mg (Arm 1)",
                        "Selinexor 60 mg (Optional Expansion Arm)"
                    ],
                    "otherNames": [
                        "OJJAARA"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of Participants with Spleen Volume Reduction 35 (SVR35) at Week 24.",
                    "description": "Measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan",
                    "timeFrame": "At Week 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants with Treatment-emergent Adverse Events (TEAEs), Severity of TEAEs, Treatment Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "From start of drug administration up to 30 days after the last dose of study treatment (approximately 48 months)"
                },
                {
                    "measure": "Proportion of Participants with Total Symptom Score 50 (TSS50) at Week 24.",
                    "description": "Measured by the Myelofibrosis Symptom Assessment Form (MFSAF) V4.0. A higher Total Symptom Score (TSS) indicates a higher disease burden and thus a worse outcome.",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Proportion of Participants with Anemia Response at Week 24 as per the International Working Group Myeloproliferative Neoplasms Research and Treatment and European Leukemia Network (IWG-MRT and ELN) Criteria",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "timeFrame": "From date of randomization to the date of death due to any cause or EoS (assessed at approximately 48 months)"
                },
                {
                    "measure": "Overall Response Rate (ORR) as per IWG MRT and ELN Criteria",
                    "timeFrame": "From Cycle 1 Day 1 (28-day cycle) up to EoS (approximately 48 months)"
                },
                {
                    "measure": "Proportion of Participants with SVR35 at Any Time Point.",
                    "description": "Measured by MRI or CT Scan.",
                    "timeFrame": "From Baseline to EoS (approximately 48 months)"
                },
                {
                    "measure": "Proportion of Participants with TSS50 at Any Time.",
                    "description": "Measured by the MFSAF V4.0. A higher Total Symptom Score (TSS) indicates a higher disease burden and thus a worse outcome.",
                    "timeFrame": "From Baseline to EoS (approximately 48 months)"
                },
                {
                    "measure": "SVR35 Response in Pre-specified MF Participant Subgroups (Including by Gender, Age, and Geographic Region)",
                    "timeFrame": "From Baseline up to EoS (approximately 48 months)"
                },
                {
                    "measure": "TSS50 Response in Pre-specified MF Participant Subgroups (Including by Gender, Age, and Geographic Region)",
                    "timeFrame": "From Baseline up to EoS (approximately 48 months)"
                },
                {
                    "measure": "Anemia Response in Pre-specified MF Participant Subgroups (Including by Gender, Age, and Geographic Region)",
                    "timeFrame": "From Baseline up to EoS (approximately 48 months)"
                },
                {
                    "measure": "SVR35 Response in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor Only",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "TSS50 Response in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor Only",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Anemia Response in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor Only",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Number of Participants with TEAEs, Severity of TEAEs, TRAEs and SAEs in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor Only",
                    "timeFrame": "From start of drug administration up to 30 days after the last dose of study treatment (approximately 48 months)"
                },
                {
                    "measure": "Area Under the Concentration-time Curve (AUC) of Selinexor",
                    "timeFrame": "Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and 2 hours post-dose on Cycle 2 Day 15 (28-day cycle)"
                },
                {
                    "measure": "Maximum Plasma Concentration (Cmax) of Selinexor",
                    "timeFrame": "Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and 2 hours post-dose on Cycle 2 Day 15 (28-day cycle)"
                },
                {
                    "measure": "Time at Which Cmax is Achieved (Tmax) of Selinexor",
                    "timeFrame": "Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and 2 hours post-dose on Cycle 2 Day 15 (28-day cycle)"
                },
                {
                    "measure": "Duration of Receptor Occupancy or Exportin 1 (XPO1) mRNA Induction",
                    "timeFrame": "From Baseline up to EoS (approximately 48 months)"
                },
                {
                    "measure": "Proportion of Participants with Post-treatment Changes in Bone Marrow",
                    "timeFrame": "From Baseline up to EoS (approximately 48 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* A diagnosis of MF or post-ET or post-PV MF according to the 2016 World Health Organization (WHO) classification of MPN, confirmed by the most recent local pathology report.\n* Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than equal to (\\>=) 450 cubic square centimeter (cm\\^3) by MRI or CT scan (results from MRI or CT imaging performed within 28 days prior to screening are acceptable).\n* Participants with DIPSS risk category of intermediate-1 with symptoms, or intermediate-2, or high-risk.\n* ECOG Performance Status less than or equal to (\\<=) 2.\n* Platelet count of 50 to less than (\\<) 100 x 10\\^9/L without platelet transfusion within 7 days prior to the first dose of selinexor.\n* Absolute neutrophil count (ANC) \\>=1.0 \u00d7 10\\^9/L without need for growth factors within 7 days prior to the first dose of selinexor.\n* Adequate liver function as defined by the following: aspartate transaminase (AST) and alanine aminotransferase (ALT) \\<= 2.5 \u00d7 upper limit normal (ULN) and serum total bilirubin \\<= 3\u00d7ULN.\n* Calculated creatinine clearance (CrCl) greater than (\\>) 15 milliliter per minute (mL/min) based on the Cockcroft and Gault formula.\n* Active symptoms of MF as determined by presence of at least 2 symptoms with a score \\>= 3 or total score of \\>= 10 at screening using the MFSAF V4.0.\n* Participants must provide bone marrow biopsy samples (samples obtained up to 3 months prior to C1D1 are permitted) at screening and during the study.\n* Participants currently not a candidate for stem cell transplantation.\n* Participants must be willing to complete the MFSAF V4.0 daily during the study for evaluating the symptom response (i.e., TSS50).\n\nKey Exclusion Criteria:\n\n* More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase).\n* Previous treatment with JAK inhibitors for MF.\n* Previous treatment with selinexor or other XPO1 inhibitors.\n* Female participants who are pregnant or lactating.\n* Prior splenectomy, or splenic radiation within 6 months prior to C1D1.\n* History of myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG), cerebrovascular accident (stroke or transient ischemic attack \\[TIA\\]), ventricular arrhythmias, congestive heart failure New York Heart Association (NYHA) class \\> 2 within 6 months of C1D1.\n* Participants unable to tolerate two forms of antiemetics prior to each dose for the first two cycles.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Karyopharm Medical Information",
                    "role": "CONTACT",
                    "phone": "(888) 209-9326",
                    "email": "clinicaltrials@karyopharm.com"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope - Duarte Main Site",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Haris Ali",
                            "role": "CONTACT",
                            "phone": "626-356-4673",
                            "email": "harisali@coh.org"
                        },
                        {
                            "name": "Haris Ali",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Maryland Oncology Hematology - Independent of SCRI/ US Oncology",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "Maryland",
                    "zip": "21044",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mohit Narang",
                            "role": "CONTACT",
                            "phone": "304-942-9220",
                            "email": "mohit.narang@usoncology.com"
                        },
                        {
                            "name": "Mohit Narang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.24038,
                        "lon": -76.83942
                    }
                },
                {
                    "facility": "Weill Cornell Medicine NewYork-Presbyterian",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ellen Ritche",
                            "role": "CONTACT",
                            "phone": "646-962-4580",
                            "email": "ritchie@med.cornell.edu"
                        },
                        {
                            "name": "Ellen Ritche",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aaron Gerds",
                            "role": "CONTACT",
                            "phone": "216-445-9840",
                            "email": "gerdsa@ccf.org"
                        },
                        {
                            "name": "Aaron Gerds",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Research Institute of the McGill University Health Centre",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Jonathan How",
                            "role": "CONTACT",
                            "email": "jonathan.b.how@mcgill.ca"
                        },
                        {
                            "name": "Jonathan How",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013921",
                    "term": "Thrombocytopenia"
                },
                {
                    "id": "D000055728",
                    "term": "Primary Myelofibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001791",
                    "term": "Blood Platelet Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000095542",
                    "term": "Cytopenia"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16680",
                    "name": "Thrombocytopenia",
                    "asFound": "Thrombocytopenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5072",
                    "name": "Blood Platelet Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3170",
                    "name": "Cytopenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000546012",
                    "term": "N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M207501",
                    "name": "Chrysarobin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1474",
                    "name": "Janus Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M256030",
                    "name": "N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide",
                    "asFound": "Expression levels",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}